Identification of a dual functional betulinic acid analog for the treatment of osteoarthritis by phenotypic screening  

作　　者：Ze-Min Lin Mai Xiang Wen-Hui Wei Shu-Hui Fan Li Chen Jie Wang Xiao-Qian Yang Chun-Hao Yang Shi-Jun He Jian-Ping Zuo 

机构地区：[1]Laboratory of Immunopharmacology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China [2]School of Pharmacy,University of Chinese Academy of Sciences,Beijing 100049,China [3]School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China [4]State Key Laboratory of Drug Research,Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China [5]Innovation Research Institute of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China [6]Experiment Center for Science and Technology,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China

出　　处：《Science China(Life Sciences)》2025年第1期300-302,共3页中国科学(生命科学英文版)

基　　金：supported by the National Natural Science Foundation of China (82374108);the Shanghai Municipal Science and Technology Major Project;the State Key Laboratory of Drug Research Program (SIMM1903ZZ-03);the CAS “Light of West China” Program;CAS Interdisciplinary Innovation Team

摘　　要：Dear Editor,Phenotypic drug discovery,which observes compound effects on physiology,has given way to targeting specific molecules,but has revived by using modern methods to find drugs based on therapeutic outcomes in disease models(Vincent et al.,2022).Osteoarthritis(OA)is a prevalent chronic joint disorder,primarily affecting knee joints,with osteoclast activation due to low-grade inflammation resulting in increased bone resorption and structural changes in the joint(Katz et al.,2021).This imbalance and the discharge of inflammatory mediators perpetuate the cycle of inflammation and tissue damage.Therefore,controlling inflammation and modulating osteoclastogenesis are critical therapeutic targets for managing OA.

关 键 词：INFLAMMATION DRUGS 

分 类 号：R914[医药卫生—药物化学]